Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 20/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.55 |
| ▸ | CDK2AP1 | O14519 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1496154 | 0.95 | CHEK1 (0.53) | CHEK1KCNH2 | |
| SCHEMBL1496019 | 0.92 | CHEK1 (0.60) | CHEK1KCNH2 | |
| SCHEMBL1496010 | 0.90 | CHEK1 (0.62) | CHEK1KCNH2 | |
| SCHEMBL1496054 | 0.90 | CHEK1 (0.56) | CHEK1KCNH2 | |
| SCHEMBL12172198 | 0.89 | CHEK1 (0.61) | CHEK1KCNH2CDK2AP1 | |
| SCHEMBL1496089 | 0.87 | CHEK1 (0.73) | CHEK1KCNH2 | |
| SCHEMBL1496152 | 0.87 | CHEK1 (0.60) | CHEK1KCNH2 | |
| SCHEMBL1496133 | 0.87 | CHEK1 (0.57) | CHEK1KCNH2 | |
| SCHEMBL29900088 | 0.85 | CHEK1 (0.76) | CHEK1KCNH2 | |
| SCHEMBL1496020 | 0.85 | CHEK1 (0.76) | CHEK1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150072987-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION | SHANGHAI HUAYU BIOTECH CO., LTD (CN) | 2015-03-12 | — | — | US | claimed |
| US-8815863-B2 | Compounds and therapeutic use thereof for protein kinase inhibition | SHANGHAI HUAYU BIOTECH CO., LTD. (CN) | 2014-08-26 | — | — | US | claimed |
| US-20120232082-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION | SHANGHAI HUAYU BIOTECH CO., LTD. (CN) | 2012-09-13 | — | — | US | claimed |
| EP-2477496-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION | Wu, Zhanggui (US) | 2012-07-25 | — | — | EP | claimed |
| WO-2011035077-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION | WU ZHANGGUI (US) | 2011-03-24 | — | — | WO | claimed |
| US-9487539-B2 | Compounds and therapeutic use thereof for protein kinase inhibition | SHANGHAI HUAYU BIOTECH CO., LTD (CN) | 2016-11-08 | — | — | US | disclosed |
| EP-2826780-B1 | Thieno[2,3-d]pyridazine derivatives and therapeutic use thereof for protein kinase inhibition | WU ZHANGGUI (US) | 2016-06-01 | — | — | EP | disclosed |
| US-20150072987-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION | SHANGHAI HUAYU BIOTECH CO., LTD (CN) | 2015-03-12 | — | — | US | disclosed |
| EP-2826780-A1 | Thieno[2,3-d]pyridazine derivatives and therapeutic use thereof for protein kinase inhibition | Wu, Zhanggui (US) | 2015-01-21 | — | — | EP | disclosed |
| US-8815863-B2 | Compounds and therapeutic use thereof for protein kinase inhibition | SHANGHAI HUAYU BIOTECH CO., LTD. (CN) | 2014-08-26 | — | — | US | disclosed |
| EP-2477496-B1 | NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION | WU ZHANGGUI (US) | 2014-04-16 | — | — | EP | disclosed |
| US-20120232082-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION | SHANGHAI HUAYU BIOTECH CO., LTD. (CN) | 2012-09-13 | — | — | US | disclosed |
| EP-2477496-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION | Wu, Zhanggui (US) | 2012-07-25 | — | — | EP | disclosed |
| WO-2011035077-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION | WU ZHANGGUI (US) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150072987-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION | CHEK2, CHEK1, PLK1 | CHEK1 2/4885KCNH2 4177/4885CDK2AP1 66/4885 |
| US-20120232082-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION | CHEK2, CHEK1, BUB1B | CHEK1 2/4885KCNH2 4004/4885CDK2AP1 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.